Results 151 to 160 of about 466,743 (315)

Gastric low-grade MALT lymphoma, high-grade MALT lymphoma and diffuse large B cell lymphoma show different frequencies of trisomy

, 1999
Gastric MALT lymphoma is a distinct entity related to Helicobacter pylori gastritis. Some studies suggest a role for trisomy 3 in the genesis of these lymphomas, but they mainly focused on low-grade MALT lymphoma.
PhM Kluin, E Schuuring, Schuuring, E, Hoeve, M.A., Krieken, J.H.J.M. van, Hopman, A.H.N., Gisbertz, I.A., Hoeve, M A, Schuuring, E., Kluin, P., van Krieken, J H, Schouten, H C, Kluin, P M, Schouten, H.C., IAM Gisbertz, FJ Bot, Gisbertz, I A, J-W Arends, Hermans, J., Arends, J.W., HC Schouten, JHJM van Krieken, A Hopman, MA Hoeve, Hermans, J, Bot, F.J., Hopman, A, J Hermans, Bot, F J, Arends, J E, Schuuring, E; id_orcid   +30 more
core   +1 more source

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Nanoparticle-based strategy for personalized B-cell lymphoma therapy

, 2016
Nicola M Martucci,1,* Nunzia Migliaccio,1,* Immacolata Ruggiero,1,* Francesco Albano,2 Gaetano Calì,3 Simona Romano,1 Monica Terracciano,4 Ilaria Rea,4 Paolo Arcari,1 Annalisa Lamberti1 1Department of Molecular Medicine and Medical Biotechnology,
Albano F, Calì G, Terracciano M, Rea I, Arcari P, Lamberti A, Romano S, Ruggiero I, Martucci NM, Migliaccio N   +9 more
core  

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

Advanced Science, EarlyView.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs, Pranay Nath, Alice Chen, Rizwan Romee, Andreia Maia   +4 more
wiley   +1 more source

MicroRNAs as B-cell lymphoma biomarkers

, 2015
Lorea Manterola,1 Marta Fernandez-Mercado,1 Erika Larrea,1 Ibai Goicoechea,1 María Arestin,1 María Armesto,1 Luiza Hernandez,1 Charles H Lawrie1,2,3 1Oncology Area, Biodonostia Research Institute, San Sebastián, Spain; 2Nuffield ...
Larrea E, Manterola L, Armesto M, Hernandez L, Goicoechea I, Arestin M, Fernandez-Mercado M, Lawrie CH   +7 more
core  

Expressió de ZAP-70 en linfòcits B normals i síndromes limfoproliferatives B [PDF]

, 2006
[cat] La Leucèmia Limfàtica Crònica (LLC), la més freqüent de les leucèmies en el món occidental, és una malaltia produïda per la proliferació i cúmul de limfòcits B madurs, actualment incurable.
Crespo Maull, Marta
core  

Prevalence profile of cutaneous T- and B-cell lymphoma in Gharbia Governorate, Egypt

Journal of the Egyptian Women’s Dermatologic Society
Background Lymphomas represent a heterogeneous group of lymphoid malignancies with varied patterns of clinical behavior and responses to treatment. The WHO classification distinguishes lymphoid neoplasms derived from precursor lymphoid cells from those ...
Nagwa M. Elwan, Dina A. Badawy, Salwa A. Atlam, Ghada F. R. Hassan   +3 more
doaj   +1 more source

Discovery of a Potent Fluorescence Polarization Probe for Identifying USP1 Allosteric Inhibitors

Advanced Science, EarlyView.
This study presents the first ubiquitin‐specific protease 1 (USP1) allosteric fluoroprobe and fluorescence polarization assay, enabling the differentiation of allosteric and catalytic site inhibitors. Further, a novel class of tetrahydroisoquinoline‐based USP1 inhibitors is designed, with compound 14a (USP1 IC50 = 29.9 nM) showing strong selectivity ...
Jiawei Cheng, Peipei Wang, Pengfei Wang, Jiamin Wang, Baiyang Li, Daqing Fang, Jian He, Xiaobei Hu, Weijuan Kan, Yubo Zhou, Chunpu Li, Jia Li, Hong Liu   +12 more
wiley   +1 more source

Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma

, 2008
Background Burkitt's lymphoma is an aggressive B-cell lymphoma characterized by typical morph 0 logical, immunophenotypic and molecular features. Gene expression profiling provided a molecular signature of Burkitt's lymphoma, but also demonstrated that a
Braziel, Rita M., Salaverria, Itziar, Gascoyne, Randy D., Rimsza, Lisa M., Chan, Wing C., Zettl, Andreas, Mueller-Hermelink, Hans Konrad, Lopez-Guillermo, Armando, Ott, German, Weisenburger, Dennis D., Delabie, Jan, Hartmann, Elena M., Rosenwald, Andreas, Boerma, Evert-Jan, Dave, Sandeep S., Wright, George W., Campo, Elias, Kluin, Philip M., Jaffe, Elaine S., Staudt, Louis M., Bea, Silvia   +20 more
core   +1 more source

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

Frontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell ...
Bei Hu, Victoria Korsos, M. Lia Palomba, M. Lia Palomba   +3 more
doaj   +1 more source